Search PubMed⌕ Search

Biomedical subjects

K Mase

Publications and source records attributed to K Mase.

50 records · Page 3Linked to original sources
PubMed1985

Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease.

A new antithrombotic drug, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-qui nolinone OPC-13013), was administered at daily oral doses of 75, 150 and 300 mg for 2 weeks in 15 patients with cerebrovascular disease including cerebral thrombosis, transient ischemic attacks and cerebral arteriosclerosis, and patient response was determined based on the degree of suppression of the platelet function. The antiplatelet-aggregating effect of the drug was determined by measuring the rate of inhibition of platelet aggregation induced by aggregation inducers such as adenosine diphosphate (ADP), collagen and epinephrine. The inhibition rates (percent difference between pre- and post-treatment rates/pre-treatment rate) obtained with the drug at 75 mg/day were 25.5, 36.5 (p less than 0.1) and 10.9% when platelet rich plasma (PRP) was added to ADP, collagen and epinephrine, respectively. The corresponding values at 150 mg/day were 34.2 (p less than 0.1), 50.7 (p less than 0.05) and 48.0% (p less than 0.1), and those at 300 mg/day were 62.1 (p less than 0.01), 71.7 (p less than 0.01) and 48.2% (p less than 0.1), respectively. The inhibitory effect of the drug thus appeared to be dose-related. Adhesiveness was also reduced by the drug, though a bleeding tendency was not indicated, and the reduction was found to be significant at 300 mg/day (p less than 0.05). The drug can, therefore, be considered to be a potent and safe antiplatelet-aggregating agent.

Administration, Oral↗
PubMed1985

Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.

A new antithrombotic drug, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013), was orally administered at 50, 100, 150 and 200 mg daily for four weeks to 24 patients with cerebrovascular diseases including cerebral thrombosis, cerebral embolism, transient ischemic attacks and cerebral arteriosclerosis. The drug effect on platelet aggregation induced by adenosine diphosphate (ADP), collagen, epinephrine and arachidonic acid and the recovery of platelet aggregation after drug withdrawal were monitored with time by determining the plasma concentrations of the drug. Prior to the repetitive administration study, the antiplatelet-aggregating effect of the drug was examined by single administration at 50 and 100 mg to six patients each. The dose of 50 mg was not sufficiently effective, but the dose of 100 mg significantly (p less than 0.05) reduced aggregation induced by collagen and arachidonic acid at 6 h suggesting the therapeutic value of the drug even by single administration. Following this study, the antiplatelet-aggregating effect of the drug was determined after four weeks of treatment. The pretreatment values for ADP-induced aggregation were 72.7, 72.1, 70.5 and 78.8% in the 50 mg/day (once daily), 100 mg/day (50 mg twice a day), 150 mg/day (50 mg three times a day) and 200 mg/day (100 mg twice a day) dosage groups, respectively. The aggregation rates determined after 4 weeks of treatment were 60.8, 56.8, 46.0 and 43.8%, respectively, and the values obtained at 100 mg/day or higher were significantly (p less than 0.05) low compared to the respective pretreatment values.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗
PubMed1985

[Clinical studies on the effectiveness of SM-4300, a new non-modified gammaglobulin preparation suitable for intravenous use, in refractory infections].

Eighteen cases of various infections, mostly having severe underlying diseases and showing no or insufficient responses to antibacterial chemotherapy, were treated with additional intravenous drip infusion of SM-4300 (2.5 or 5 g, once a day, for 1-3 days). Eight of the cases were excluded from the assessment of the effectiveness, as they died too early, or as their fever was supposed to have been "tumor fever" retrospectively. SM-4300 was found to be effective in 2 out of 5 septicemia cases, in 3 pneumonia cases, including 1 complicated with septicemia, out of 4, and also in 1 patient with liver abscess, as well as in another of meningitis caused by Campylobacter fetus; i.e. the efficacy rate was estimated as 60% in total. Any side effects attributable to SM-4300 were observed in none of the 18 cases. These results obtained seem to endorse the usefulness of the preparation.

Adolescent↗
PubMed1983

Mechanism of inhibition of contraction by cadmium in guinea-pig taenia coli.

Further evidence about the mechanism of the inhibition of contractions caused by cadmium ions (Cd2+) in guinea-pig taenia coli has been sought. Cd2+ at a concentration of 0.5 mM completely inhibited the high-K (40 mM)-induced contraction within 3-5 min. Cd2+ did not shift the Ca2+-induced concentration-response curve to the right in Ca2+-free K+ depolarized muscle, although it reduced the Ca2+ response size. The K+-induced increase in tissue calcium content and 45Ca uptake determined by the lanthanum method was significantly reduced in the presence of Cd2+ (0.5 mM) and the contractions of the glycerolated taenia coli were inhibited with increasing Cd2+ (0.001-0.5 mM). Muscle strips, incubated in a medium containing 0.5 mM Cd2+, accumulated greater amounts of cadmium than within the extracellular space. It is suggested that the inhibitory action on tension produced by Cd2+ in taenia coli may result from the interference of calcium permeability at the cell membrane. There is the possibility that Cd2+ acts on the contractile system of the muscle.

Animals↗
PubMedDate not supplied

Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy.

A 59 year-old woman showed rapidly progressive glomerulonephritis during immunotherapy for metastatic renal cell carcinoma. She received unilateral nephrectomy and cytotoxic T lymphocyte (CTL) therapy for the treatment of retroperitoneal lymph node metastasis of renal cell carcinoma. With CTL therapy, her retroperitoneal lymph node mass decreased in size. One year after the third round of CTL therapy, her serum creatinine was increased and massive proteinuria occurred. Her renal biopsy specimen revealed necrotizing and crescentic glomerulonephritis with immune complex deposition. Her retroperitoneal lymph node mass continued to decrease in size. Consequently, for the purpose of avoiding interfering with the CTL therapy, we performed double filtration plasmapheresis (DFPP) monotherapy for removal of immune complexes without using immunosuppressive drugs or prednisolone. After 24 sessions of DFPP, her serum IgG was reduced from 3,942 mg/dL to 2,400 mg/dL, and proteinuria (from 9.0 g/day to 0.9 g/day) and renal function (serum creatinine; from 5.6 mg/dL to 2.2 mg/dL) also improved. However, 3 months after the final DFPP, she expired due to perforation of the colon. The autopsy sample of the kidney showed that most of the glomeruli were obsolescent, but immunoglobulin depositions were reduced and necrotizing lesions were diminished. In the patients with RPGN associated with renal cell carcinoma, renal functional recovery has not been observed upon immunosuppressive treatment. Consequently, plasmapheresis is considered to be one of the effective and safe methods for patients with this association. We also discuss previous reports of RPGN associated with renal cell carcinoma, or RPGN after cancer immunotherapy.

Biopsy↗